Lifesci Capital Weighs in on Neurogene FY2025 Earnings

Neurogene Inc. (NASDAQ:NGNE) – Stock analysts at Lifesci Capital issued their FY2025 earnings per share estimates for Neurogene in a report released on Monday, January 26th. Lifesci Capital analyst P. Dolezal forecasts that the company will post earnings per share of ($4.26) for the year. Lifesci Capital has a “Outperform” rating and a $50.00 price target on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. Lifesci Capital also issued estimates for Neurogene’s Q4 2025 earnings at ($1.17) EPS, Q1 2026 earnings at ($1.19) EPS, Q2 2026 earnings at ($1.21) EPS, Q3 2026 earnings at ($0.99) EPS, Q4 2026 earnings at ($1.00) EPS, FY2026 earnings at ($4.33) EPS, FY2027 earnings at ($3.96) EPS, FY2028 earnings at ($0.63) EPS, FY2029 earnings at $5.80 EPS and FY2030 earnings at $12.83 EPS.

Neurogene (NASDAQ:NGNE) last posted its earnings results on Thursday, November 13th. The company reported ($0.99) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.27.

Other research analysts have also recently issued reports about the company. Wall Street Zen cut Neurogene from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Neurogene in a research report on Tuesday, January 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a research note on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Neurogene currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

Neurogene Price Performance

Shares of Neurogene stock opened at $19.87 on Wednesday. The company’s 50 day moving average price is $19.69 and its two-hundred day moving average price is $22.01. The firm has a market capitalization of $307.79 million, a P/E ratio of -4.83 and a beta of 1.60. Neurogene has a fifty-two week low of $6.88 and a fifty-two week high of $37.27.

Institutional Trading of Neurogene

A number of large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets lifted its stake in shares of Neurogene by 89.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after purchasing an additional 978 shares during the period. PNC Financial Services Group Inc. raised its holdings in Neurogene by 43.6% during the second quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock worth $61,000 after buying an additional 1,232 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Neurogene by 17.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after acquiring an additional 1,059 shares during the last quarter. Bridgeway Capital Management LLC purchased a new stake in shares of Neurogene in the third quarter worth approximately $187,000. Finally, Brevan Howard Capital Management LP purchased a new stake in Neurogene in the 3rd quarter valued at $223,000. 52.37% of the stock is currently owned by institutional investors and hedge funds.

Neurogene News Roundup

Here are the key news stories impacting Neurogene this week:

• Positive Sentiment: LifeSci Capital initiated coverage with an Outperform rating and a $50 target — the call signals sell‑side interest and a material upside scenario (~151.6% above the recent $19.87 reference level), which often drives buying and analyst‑led flows. Lifesci Capital Begins Coverage on Neurogene
• Neutral Sentiment: LifeSci published a detailed multi‑year earnings model showing a pathway from near‑term losses to meaningful profitability in FY2029–FY2030 (FY2029 $5.80 EPS; FY2030 $12.83 EPS). This long‑term upside supports the $50 target but is highly dependent on successful program execution and commercialization. LifeSci Capital initiates coverage of Neurogene (NGNE)
• Negative Sentiment: Near‑term estimates remain deeply negative: LifeSci projects sustained quarterly losses across FY2025–FY2027 (several quarters near ~$1.00 loss each) and FY2026 EPS of roughly ($4.33). Consensus full‑year EPS remains negative (~($4.27)), so the company faces execution and financing risk before reaching the modeled profitable years. Lifesci Capital Begins Coverage on Neurogene

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.